Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

Clas­si­cal Hodgkin lym­phoma was the first blood can­cer that Mer­ck’s Keytru­da was ap­proved to treat. Three years af­ter that OK ar­rived — kick­ing off a spate of new in­di­ca­tions for the star PD-1 in­hibitor — the com­pa­ny fi­nal­ly has some sol­id ev­i­dence of its ef­fect.

Build­ing on the over­all re­sponse rates that con­vinced FDA reg­u­lars to hand down an ac­cel­er­at­ed ap­proval in March 2017, Mer­ck said Keytru­da hit a co-pri­ma­ry end­point on pro­gres­sion-free sur­vival in the Phase III con­fir­ma­to­ry tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER